Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Passage Bio (PASG)
NASDAQ:PASG
Holding PASG?
Track your performance easily
PASG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.58 - $1.79
Previous Close$0.73
Volume148.83K
Average Volume (3M)257.25K
Market Cap
$44.92M
Enterprise Value-$20.70M
Total Cash (Recent Filing)$91.77M
Total Debt (Recent Filing)$26.15M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Nov 12, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding61,767,286
10 Day Avg. Volume298,709
30 Day Avg. Volume257,251
Standard Deviation0.23
R-Squared0.08
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.48
Price to Sales (P/S)184.84
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-85.21
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.28
Forecast
1Y Price Target
$10.00Price Target Upside1326.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Passage Bio News
PremiumCompany Announcements
Passage Bio Reveals Promising Gene Therapy Trial Results
PremiumCompany Announcements
Passage Bio Appoints Thomas Kassberg to Leadership Team
PremiumCompany Announcements
Passage Bio Presents Updated Corporate InsightsBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe GM1 update built on data presented in December 2022, providing a stronger signal of dose-dependent biomarker response.
Drug Development ProgressPassage is prioritizing development of PBFT02 in other neurodegenerative diseases potentially addressable through progranulin modulation.
Financial StabilityPassage's cash runway remains at 4Q25 with the strategic shift.
Bears Say
Clinical Trial ResultsThe 4th patient (P7; early infantile) did not show improvement in CSF beta-Gal activity at 180 days post-treatment.
Clinical Trial ResultsData from cohorts 1 and 3 receiving Dose 1 showed a much more modest increase in CSF beta-Gal activity with no patient achieving average healthy adult levels, and no reduction in CSF GM1 gangliosides.
Operational ChallengesThe company’s progress to date has been slower than anticipated because of patient identification/enrollment and handling multiple clinical programs at once.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PASG FAQ
What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $0.57 and its highest was $1.79 in the past 12 months.
What is Passage Bio’s market cap?
Currently, no data Available
When is Passage Bio’s upcoming earnings report date?
Passage Bio’s upcoming earnings report date is Nov 12, 2024 which is in 53 days.
How were Passage Bio’s earnings last quarter?
Passage Bio released its earnings results on Aug 08, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.309 by $0.049.
Is Passage Bio overvalued?
According to Wall Street analysts Passage Bio’s price is currently Undervalued.
Does Passage Bio pay dividends?
Passage Bio does not currently pay dividends.
What is Passage Bio’s EPS estimate?
Passage Bio’s EPS estimate is -$0.24.
How many shares outstanding does Passage Bio have?
Passage Bio has 61,767,284 shares outstanding.
What happened to Passage Bio’s price movement after its last earnings report?
Passage Bio reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.309. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of Passage Bio?
Among the largest hedge funds holding Passage Bio’s share is Versant Venture Management, LLC. It holds Passage Bio’s shares valued at 3M.
---
Passage Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (1326.53% Upside)
$10.00 (1326.53% Upside)
Blogger Sentiment
Bullish
PASG Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 933.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $146.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.41%
12-Months-Change
Fundamentals
Return on Equity
-63.55%
Trailing 12-Months
Asset Growth
-35.26%
Trailing 12-Months
Company Description
Passage Bio
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
---
PASG Company Deck
---
PASG Earnings Call
Q4 2023
0:00 / 0:00
---
PASG Stock 12 Month Forecast
Average Price Target
$10.00
▲(1326.53% Upside)
Technical Analysis
Allogene Therapeutics
―
Adaptimmune Therapeutics
―
Gritstone Oncology
―
Fate Therapeutics
―
Best Analysts Covering PASG
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-25.00%
reiterated a buy rating 9 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -25.00% per trade.
---